activity of protein So60% , of protein Co65% and of factor XIIo70%. No association was found between VT and acquired thrombophilia, by comparing presence versus absence of persistent antiphospholipid (Asserachrom APA IgG IgM, Diagnostica Stago) and anticardiolipin antibodies and lupus anticoagulant, of plasma level of fasting homocysteine 420 mcrM/l and of factor VIII:C 4180%. The presence of at least one inherited or acquired prothrombotic marker was found in all patients with VT grade II compared to 60% of patients without VT (P ¼ 0.02). Thus, thrombophilia was not related to incidence of VT but to severity of VT; well-designed prospective studies should be encouraged to implement routine screening in these children. Other factors investigated as possibly related with VT (ANCo500/mmc at time of CVL insertion, CVL malfunctions and infections, low plasma AT or AT infusions during L-Asp treatment) were not statistically significant in our study.
Well-grounded guidelines for the prevention and treatment of CVL-VT in children with ALL are still lacking. Delaying CVL insertion until the end of induction and using internal ports can be suggested 5 for older children. The primary finding in our study, although limited by patient numbers, was the increased risk of VT in children with a high catheter diameter/body surface ratio, thus a feasible recommendation should be that size of the catheter be tailored to the size of the single patient. Concerning treatment of asymptomatic CVL-VT, prophylaxis of thrombosis should be considered if the catheter must remain in place; however, the need for full-dose anticoagulation is still not clear. Removal at the beginning of maintenance chemotherapy should be recommended.
The present study confirms that the risk of CVL-related VT is significant in children affected by ALL and with early inserted CVL, and properly designed studies are needed to evaluate the effect of VT on overall outcome and quality of life of these children. Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative/myelodysplastic disorder of young children. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy, and a recent report from the European working group on myelodysplastic syndrome in Childhood (EWOG-MDS) indicates an event-free survival (EFS) of 52% at 5 years after HSCT. 1 Relapse remains the major cause of treatment failure, affecting about one-third of the patients following transplantation. 1 The optimal treatment strategy for patients who relapse after HSCT remains unknown. Withdrawal of immunosuppressive therapy is usually the first measure, which by itself can control the disease in a small number of patients, but the outcome of children given donor leukocyte infusion (DLI) for JMML recurrence is generally poor. 2 A second HSCT is another option, but data on the possibility of cure offered by this treatment are not available. Here, we summarize the outcome of second HSCT in 24 children with JMML relapsing after first-allogeneic HSCT.
Between July 1987 and August 2003, 183 patients with JMML registered in the retro-and prospective studies of EWOG-MDS underwent allogeneic HSCT. Sixty-eight patients relapsed after HSCT, and 26 of these patients received a second graft. Of the 26 patients, 24 (17 boys and seven girls) are included in this study, two patients were excluded owing to insufficient data. Transplants were performed at 15 centers in seven countries:
and Sweden (n ¼ 1). Informed parental consent for participation in EWOG-MDS studies were obtained from all patients. At diagnosis, the median age was 3.6 years (range, 0.7-8.2 years). The median white blood count, monocyte and platelet counts were 23.8 (range, 3.6-97.1), 5.5 (range, 1.0-29.0) and 45.0 (range, 9.0-373.0) Â 10 9 /l, respectively. The percentage of blasts in peripheral blood (PB) and bone marrow (BM) varied between 0 and 14% (median 3%) and between 2 and 20% (median 7%), respectively, and the hemoglobin F ranged from 0 to 64% (median 20%). Cytogenetic analysis showed a normal karyotype in 15 patients, monosomy 7 in 7, and del(22) or a complex karyotype in one patient each. A clinical diagnosis of neurofibromatosis type 1 was established in two boys. PTPN11 and RAS mutations were investigated in 17 patients and somatic mutations were detected in six and two children, respectively.
Neutrophil and platelet engraftment were defined as the first of three consecutive days of a neutrophil count 40.5 Â 10 9 /l and an unsupported platelet count 450 Â 10 9 /l. Relapse was diagnosed by the presence of an elevated blast count in PB or BM, clinical signs of relapse with BM hypercellularity or absence of megakaryocytes, or recurrence of an abnormal karyotype. Patients were considered valuable for acute and chronic graft-versus-host disease (GVHD) if they survived at least 7 and 100 days after HSCT, respectively. A patient who never achieved remission after a second HSCT was considered to have relapsed on day 1 of post-transplantation.
Prior to first HSCT, 13 patients had been splenectomized and 4 patients had received acute myeloid leukemia (AML) therapy, whereas no patient was splenectomized or received AML therapy between first and second HSCT. Six of the seven patients who received DLI showed no response to DLI; one patient temporally achieved complete chimerism but relapsed 33 days later and did not respond to a second course of DLI. Details of DLI were recently reported. 2 The percentage of blasts in BM at first and second HSCT was similar with a median of 7% (0-85%) and 8% (0-78%), respectively. The median time intervals were as follows: diagnosis to first HSCT 164 days (range, 29-475 days), first HSCT to diagnosis of hematological relapse 160 days (range, 69-788 days) and first to second HSCT 260 days (range, 92-907 days).
For first HSCT, a preparative regimen with busulfan (BU), cyclophosphamide (CY), and 7melphalan was used in 19 children, whereas total body irradiation (TBI) was employed in three patients (Table 1 ). In contrast, 18 patients received a TBI regimen for second HSCT with 10 of these patients given a preparative regimen including TBI, thiotepa and fludarabine. For second HSCT, 14 children were transplanted from an human leukocyte antigen (HLA)-matched family donor (MFD), one from a haploidentical father, seven from a matched unrelated donor (MUD) and two from a one or two antigen mismatched unrelated donor (MMUD). The same donor was employed for both first and second HSCT in 19 of the 24 patients. In the other five patients the donors for first/second HSCT were MFD/MFD (the donors are HLA identical siblings), MUD/MUD (the donors are HLA identical twins), MUD/MUD, twin/MUD and MFD/2 antigen MMUD. Stem cell source for second HSCT was BM and PB in 16 and eight patients, respectively. Whereas the majority of patients were transplanted from the same donor, immunosuppressive therapy for GVHD prophylaxis in second HSCT was reduced in many patients. Methotrexate was administered to 14 and five patients and anti-thymocyte globulin to nine and four patients for first and second HSCT, respectively. In 10 patients, the initial dose of CSA for the second allograft was reduced as compared with first HSCT.
After second HSCT, 23 of 24 patients engrafted. One patient (NL002) with engraftment failure died from an Aspergillus infection. The median time to neutrophil and a platelet engraftment was 16 days (range, 8-36 days) and 23 days (range, 13-89 days), respectively. Acute GVHDXgrade II developed in 13 patients after second HSCT (Table 1) . Among 20 patients at risk, six patients developed chronic GVHD, which was extensive in four cases. Both acute and chronic GVHD were more frequently observed after second HSCT as compared with first HSCT. Infections were common complications diagnosed in 14 patients; they were of bacterial origin in eight cases, fungal in two and viral in seven cases. Five of these patients had pneumonia, one patient developed Epstein-Barr virus-associated lymphoproliferative disease which was successfully treated by anti-CD20 monoclonal antibody. Veno-occlusive disease (VOD) of the liver was diagnosed in four patients.
Five patients (21%) died due to transplant-related causes: one due to engraftment failure, one due to acute GVHD, one due to VOD and acute GVHD, and two children with chronic GVHD died of pneumonia and pneumococcal sepsis ( Table 1 ). The 5-year cumulative incidence of transplant-related mortality (TRM) was 27% (95% CI, 7-47%), death occurred at a median of 65 days (range, 30 daysÀ4.9 years) after second HSCT (Figure 1a ). Nine patients (38%) relapsed at a median of 231 days (range, 1 dayÀ3.5 years) after second HSCT, the 5-year cumulative incidence of relapse being 40% (95% CI, 24-56%). In the absence of BM involvement, one patient (SC044) had an extramedullary relapse of JMML with monosomy seven in the orbit and humerus bone. Although the chloroma resolved with local radiotherapy, the patient died of progressive pulmonary leukemic infiltrates. Another patient (D051) underwent a third HSCT from the same sibling donor used for first and second HSCT, but died of intracerebellar hemorrhage.
Ten patients (43%) are alive in remission after a median observation time of 3.3 years (range, 1.2-15.8 years). The probability for leukemia-free survival (LFS) at 3 and 5 years are 50% (95% CI, 30-70%) and 32% (95% CI, 8-56%), respectively (Figure 1b) . The Karnofsky/Lansky score of patients alive is 100% in seven patients, 90% in two patients and 20% in one patient suffering from severe chronic GVHD with pulmonary involvement, hypertension and contracture of extremities.
Age, cytogenetics, BM blast count at first and second HSCT, donor (MFD vs other donor), source of stem cells (BM vs PB), interval between first HSCT and relapse (o6 months vs 46 months) or interval between first and second HSCT (o1 year vs 41 year) had no significant impact on survival or relapse rate after second HSCT. In addition, acute GVHD after both first and second HSCT had no impact on outcome. However, none of the six patients who developed chronic GVHD after second HSCT experienced leukemia recurrence. On the other hand, eight out of 14 patients without chronic GVHD relapsed after second HSCT (P ¼ 0.04).
Several large reports on the results of second HSCT for relapse after first HSCT in patients with various types of leukemias have been published. 3 These analyses generally show a poor outcome with a high rate of relapse and TRM. Here, we report the result of 24 patients with JMML who underwent HSCT for relapse after first HSCT. Surprisingly, LFS, RI and TRM were comparable to those of some previously published analyses for Abbreviations: HSCT, hematopoietic stem cell transplantation; MFD, matched family donor; MUD, matched unrelated donor; MMFD, mismatched family donor; MMUD, mismatched unrelated donor; BM, bone marrow; PB, peripheral blood; CB, cord blood; BU, busulfan; CY, cyclophosphamide; Mel, melphalan; VP16, etoposide; Thio, thiotepa; TBI, total body irradiation; Flu, fludarabine; AraC, cytosin arabinoside; IDA, idarubicin; GVHD, graft-versus-host disease; CSA, cyclosporine (initial dose: mg/kg/day); MTX, methotrexate; ATG, anti-thymocyte globulin; TCD, ex vivo T-cell depletion; a/cGVHD, acute/chronic graft-versus-host disease; NE, not evaluable; TRM, tansplant-related mortality; VOD, veno-occlusive disease of the liver; CR, complete remission. a Different donor for 1st and 2nd HSCT (n ¼ 5).
Letters to the Editor first HSCT in JMML. 1, [4] [5] [6] As the donor was the same for first and second HSCT in the majority of patients, differences in GVHD prophylaxis and conditioning regimen should have influenced the possibility of rescuing some patients through second HSCT. As shown in Table 1 , less-intensive GVHD prophylaxis was generally employed during second HSCT as compared with first HSCT. It is reasonable to speculate that reduced immunosuppressive therapy led to a stronger graft-versus-leukemia (GVL) effect and resulted in a favorable outcome. Limited patient number and heterogeneity in donor and stem cell source prohibited formal analysis of this hypothesis; however, support is provided by the observation that none of the six patients who developed chronic GVHD after second HSCT relapsed. Previous published reports on first HSCT in JMML have also shown that chronic GVHD is associated with a favorable outcome. 4, 6 All together these results suggest the role of GVL in JMML.
There are no reports on first HSCT in JMML indicating that TBI offers an advantage over a BU containing preparative regimen. 4, 7 Therefore, BU/CY/melphalan has been applied for cytoreduction prior to HSCT in the recent EWOG-MDS study, which resulted in EFS of approximately 50% at 5 years. 1 The majority of patients (n ¼ 18) presented here received a BUcontaining regimen for first HSCT and a TBI-based regimen for second HSCT, and nine out of 18 are alive in remission. Chang et al. 8 reviewed previous reports on patients with JMML who underwent a second HSCT and observed that the outcome of second HSCT for relapse after was inferior in patients given TBI for first HSCT and non-TBI regimen for second HSCT (one of four patients alive) as compared to patients who were given a non-TBI regimen for first HSCT and TBI for second HSCT (six of seven patients alive). In our study, there were only three patients who were given TBI for first HSCT, all of them died after second HSCT. The report on HSCT in JMML from the Seattle group includes six patients who underwent second HSCT using TBI/ CY7BU and BU/CY regimens for first and second HSCT, respectively. 5 Only one of the six patients was alive in remission after second HSCT. In view of these data and of the results obtained in this study, it seems reasonable to employ a non-TBI regimen to avoid late sequels for first HSCT and to reserve TBI for those patients with JMML who may need a second HSCT.
Although most of the previous reports on second HSCT for other forms of leukemia have shown that early relapse after first HSCT is a poor prognostic factor, 3 we found no difference in outcome between early or late relapse in JMML patients. In addition, there was no inferior outcome for patients retransplanted within 1 year of the first HSCT. Age is the most important prognostic factors in JMML, influencing the probability of both relapse and survival. 1, 4 The high-median age at initial diagnosis (3.6 years) of our cohort reflects the fact that older patients have a higher risk of relapse after first HSCT. 1, 4, 7 However, age did not have any impact on outcome of second HSCT. In this study all patients transplanted from a different donor for first and second HSCT died. Therefore, no apparent benefit to employ a different donor for second HSCT was observed. However, the number of patients is too small to comment on the choice of donor.
In conclusion, current results of second HSCT in JMML are superior to those obtained with DLI 2 and, surprisingly, similar to those reported for first HSCT.
1,4-6 Second HSCT from the same donor should be considered the treatment of choice for patients with JMML experiencing leukemia recurrence. Longer follow-up is needed to evaluate the long-term outcome of these patients. Letters to the Editor
